Positive Processes and Transition to Health - Single-Session (PATH-SS)
Part of paid clinical trials in Cleveland, Ohio.
- Sponsor
- Case Western Reserve University
- Study ID
- NCT06900712
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- PATH-SS — BEHAVIORALThis single-session intervention includes the following components: * Providing the PATH-SS rationale. * A review of life events (PATH of life: negative and positive). * A verbal narrative of the sexual assault (revisiting and processing as is done in imaginal exposure) * Reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. In positive reminiscence, clients vividly remember the positive event providing details and focus on positive emotions. The therapist will encourage savoring of the experience and encourage facial expression of the positive emotions, so that clients do not dampen, avoid, or minimize the experience. This is particularly relevant with depression. * Summary of content, integration and consolidation of learning, application of new learning and resilience in real life as next steps.
Study Details
The goal of this clinical trial is to test a brief, new psychotherapy (called Positive Processes and Transition to Health - Single Session, or PATH-SS) that aims to provide relief for people who are suffering after experiencing a sexual assault. This research will explore whether this new psychotherapy reduces sexual assault related distress, including posttraumatic stress and depression symptoms. The main questions it aims to answer are: Does PATH-SS leads to improvements in PTSD and depression symptoms (pre- to post- and 1-month follow-up)? Do participants perceive PATH-SS to be acceptable, helpful, and do they complete/adhere to treatment? Participants will complete a pre-treatment/baseline assessment to confirm eligibility, and those who are eligible will receive the single-session intervention and will complete a post-treatment and a 1-month follow-up assessment of stressor-related symptoms.
Key Dates
- Start date
- Jul 17, 2025
- Status verified
- Apr 2026
- Primary completion
- Aug 31, 2026
- Completion
- May 31, 2027
Study Design
- Enrollment
- 45 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: PATH-SSThis single-session intervention includes the following components: * Providing the PATH-SS rationale. * A review of life events (PATH of life: negative and positive). * A verbal narrative of the sexual assault (revisiting and processing as is done in imaginal exposure) * Reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. In positive reminiscence, clients vividly remember the positive event providing details and focus on positive emotions. The therapist will encourage savoring of the experience and encourage facial expression of the positive emotions, so that clients do not dampen, avoid, or minimize the experience. This is particularly relevant with depression. * Summary of content, integration and consolidation of learning, application of new learning and resilience in real life as next steps.
Primary Outcome Measure
PTSD Symptom Scale-Interview (PSS-I-5; Foa et al., 2016) [ Time Frame: From baseline to follow-up at 1 month after treatment completion ]
Central Contacts
- Norah Feeny, PhD(216) 368-2695
- Jenna Bagley, MA(216) 800-8492
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Case Western Reserve University | Cleveland | Ohio | 44106 | Norah C Feeny, PhD (PRINCIPAL_INVESTIGATOR) Jenna M Bagley, MA (SUB_INVESTIGATOR) |
Find similar trials in Cleveland, OH
Related Studies
- Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)PHASE4 · Recruiting · University of Cincinnati · Cincinnati, Ohio
- A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.PHASE3 · Recruiting · AbbVie · Bentonville, Arkansas
- A Precision Medicine Approach to Target Engagement for Emotion RegulationRecruiting · Matthew Southward, PhD · Columbus, Ohio
- Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS MeasurementsEnrolling By Invitation · Kernel · Costa Mesa, California